ANZCTR search results

As hospitals move towards modern interventional suites, this study aims to identify potential safety risks related to ambient light-related performance deficiencies. Specifically, the aims are to measure the influence of spectral selection in the operating theatre and interventional suite environments and to interpret safety risks for patients in relation to the performance of anaesthetic staff in blue and green ambient light conditions. Blue and green spectral conditions will negatively affect the ability of anaesthetic staff to correctly detect colour hues using the Farnsworth test and diminish performance in a drug labelling matching task, in staff who performed adequately in white light conditions. This may indicate the potential hazards of incorrect drug identification, impaired patient monitoring performance and delayed clinical response in clinical practice.

This study aims to implement and develop the identification of tumour mutations present at baseline in patients with marginal zone lymphoma and determine whether certain mutations can predict patients’ clinical outcome and survival. Whom is it for? You may be eligible to join if you are 18 years old or over and enrolled in the BeiGene BGB-3111-214 trial at one of the Australian sites as well as the Australasian and Leukaemia Group National Blood Cancer registry (ALLG NBCR). Study details All participants who consent to take part in this study will be asked to donate duplicate buccal swabs at baseline and 30ml of blood in addition to the blood draws already performed as part of the BeiGene BGB-3111-214 clinical trial. Additional lymph node and bone marrow biopsies may be required in some cases. It is hoped that this pilot study will contribute to the identification of tumour mutations that may affect patients' responses to treatment and therefore broaden our knowledge of the mechanisms underpinning resistance to treatment.

Platinum C will collect information on people who have hepatitis C virus infection and the effects of hepatitis C treatment. We aim to work out how effective new hepatitis C treatments are, and to find out what things influence their outcomes, including the type of treatment they have, how well they adhere to treatment, and major life disruptions. We aim to understand which people are unlikely to take all of their hepatitis C medications and if and how this affects their response to treatment. We will ask some additional questions about general well-being before, during and after treatment. We expect this information will help researchers find ways to help more people to get tested, treated and cured of hepatitis C infection.

Every year, approximately 140,000 Peripherally Inserted Central Catheters (PICCs) are inserted in Australia in both children and adults to provide a route of administration for anti-cancer therapies, nutrition and antimicrobials for acute and chronically ill patients. This is despite 30% of PICCs failing prior to completion of treatment due to: deep vein thrombosis (DVT), occlusion, breakage or catheter-associated bloodstream infection (CABSI) including Staphylococcus aureus BSI (SAB). The proposed project will test three different Peripherally Inserted Central Catheter materials (two novel catheters and one standard care) to determine efficacy in preventing PICC complication and failure. The project is to be completed across The Queensland Children’s, Royal Brisbane and Women’s and Princess Alexandra Hospitals. Our investigator group consists of experienced researchers and clinicians from each of these hospitals areas as well as the University of Queensland and Griffith University.

The purpose of this study is to evaluate the safety, Pharmacokinetics and Pharmacodynamics of AR882. This study will be conducted in two parts. There will be up to 9 cohorts with 8 subjects per cohort. Part 1 will evaluate single ascending doses of AR882 and Part 2 consists of cohorts to evaluate the pharmacokinetics of AR882 under various conditions. Part 1 (Cohorts 1 to 5): Subjects in each cohort will be randomized to receive treatment with AR882 or placebo. Subjects randomised to Cohort 1-5 will ingest an oral suspension of AR882 of Dose A, Dose B, Dose C, Dose D and Dose E respectively after an overnight fast of at least 10 hours and will remain fasted until at least 4 hours post-dose. Part 2 will include Cohorts 6 to 9. Cohort 6 is a stand-alone, fed-state cohort. Subjects randomised to Cohort 6 will ingest the oral suspension of AR882 (Dose B) approximately 30 minutes after subjects begin to consume a high-fat, high-calorie breakfast. Subjects randomised to Cohort 7 will ingest the oral capsule of AR882 (Dose B) after an overnight fast of at least 10 hours and subjects will remain fasted until at least 4 hours post-dose. In Cohort 8 and 9 , Subjects will ingest allopurinol/Febuxostat after an overnight fast of at least 10 hours and will remain fasted until at least 4 hours post dose. In the AR882 combination treatment, subjects will ingest AR882 first immediately followed by ingestion of Allopurinol/Febuxostat.

Many people with lung and heart conditions have persistent breathlessness, even when they are receiving the best possible medical care for their condition. Breathlessness Intervention Services have been shown to reduce people’s distress and improve their confidence to manage breathlessness in the UK and Canada but so far these services have not been studied or made available in South Australia. This study will evaluate the feasibility and outcomes of a home-based brief intervention for people with chronic breathlessness due to lung or heart conditions, involving 2-4 visits and 3-4 telephone contacts for assessment and therapy by nurse and physiotherapist using non-drug, evidence-based symptom management therapies that fit the patient’s needs.

The fibrotic interstitial lung diseases (fILD) is a group of debilitating chronic lung conditions that are characterised by scarring of lung tissue, dyspnoea on exertion and significant physical impairment. Exercise training is recommended for people with fILD in improving breathlessness and exercise tolerance. However, despite the best efforts of patients and clinicians, many of those who participate are not attaining its benefits. The current exercise training strategies of moderate intensity continuous training may not be well suited to fILD. High intensity interval training, short bouts of high-intensity exercise regularly interspersed with periods of rest or light exercise may be an alternate exercise training option for people with fILD. People with fILD will be recruited and randomly allocated to receive either the traditional PR model of moderate intensity continuous training or high intensity interval training. The aim of this study is to determine to whether high intensity interval training is better than the current method of continuous exercise training at moderate intensity in improving exercise tolerance, breathlessness and quality of life in people with fILD.

A randomized controlled trial is designed to assess the impact of Azithromycin in reducing infectious morbidity from emergency cesarean sections at Redlands Hospital. The population undergoing emergency cesarean sections will be the focus of the research project. Adding Azithromycin to the pre-operative antibiotic regime (of Intravenous Cefazolin and topical Iodine Vaginal Cleansing) is hypothesized to be more effective at reducing post-caesarean section infection rates than the current standard pre-operative antibiotic regime alone.

The aim of this study is to test a new way of delivering a diet and lifestyle intervention through technology. Participants in this study will be instructed to start consuming a Mediterranean diet, and to increase their daily step count, for 12 weeks. Instructions on how to do this will be provided via a researcher-designed website and a virtual health coach. The virtual health coach will be accessible through an instant messaging service called Slack. A fitness band will be used to monitor daily step count. We believe that a 12-week Mediterranean diet lifestyle intervention can be delivered and monitored successfully through a website with virtual assistant technology and wireless wearables.

There is little research regarding the efficacy of CPR in obese patients. Using a simulation model we have previously demonstrated that the adequacy of chest compressions in morbidly obese mannequins is compromised, predominantly in the domains of achieving adequate compression depth and allowing sufficient time for chest wall recoil during CPR. The Bariboard(TM) is a device that purports to aid in the redistribution of forces applied to the anterior chest wall in order to improve the adequacy of chest compression. There have been no empirical trials using this device. Aim of Study: The primary aim of this study will be to explore whether the adequacy of chest compressions can be improved using a mechanical device (Bariboard(TM)) to better distribute the mechanical forces applied to the anterior thorax during CPR. Primary outcome: * To measure the efficacy of chest compressions using a previously described model of morbid obesity with and without a mechanical device that raises the thoracic cage. This will use the digital mannequins to record the quality and adequacy of chest compressions over a period of 2 minutes of uninterrupted CPR. Effective CPR will be defined as a composite measure of adequate depth of compression, adequate time for recoil at an adequate rate for >90% of compressions delivered. Secondary outcomes: * Adequacy of each component of CPR (namely rate, depth of compressions and adequate recoil). * Time taken for participants to fatigue when performing CPR on a morbidly obese mannequin. It is known that the maximum amount of time a member of staff can perform effective CPR is 2 minutes in a normal scenario. * Participant discomfort/pain experienced during CPR. * The association between staffs' perceived effectiveness and the recorded adequacy of chest compressions.